Yunnan Baiyao Group To Revisit Fundraising
This article was originally published in PharmAsia News
Executive Summary
Yunnan Baiyao Group, a leading TCM company in China, has unconfirmed plans to try again to get private financing, according to industry insiders. Sources disclose that the firm has been experiencing business slowdown since 2007 due to production capacity shortfalls while its relocation project requires a large investment. The capital raised will be used to construct its new production park and fund-fixed assets. The manufacturing base, with a phase one investment of 1.08 billion yuan ($157 million), is designed to produce 14 formulations and has capacity to expand its current output five-fold to reach 10 billion yuan. It will introduce up-to-date pharmaceutical equipment from Germany to upgrade the production system's automation control level and efficiency. (Click here for more - Chinese Language)
You may also be interested in...
News We’re Watching: AI Safety Partnership; Boston Scientific Recalls; New Cancer, STI Tests; VR
This week, the US and UK announced a partnership to promote AI safety. Boston Scientific recalls embolic agent. LumiCell received FDA approval for its imaging agent to detect residual cancer. Scout receives an award to develop an STI test; and Osso VR leverages the Apple Vision Pro for VR medical training.
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Pink Sheet Podcast: Leqembi Spending, Woodcock’s Next Act, Pneumococcal Vaccine Development
Pink Sheet editors discuss Medicare spending projections for the Alzheimer’s treatment Leqembi, Janet Woodcock’s new post-FDA role, and ongoing preparations for new pneumococcal vaccines that will reach the market soon.